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COMMENTARY
Denervation of Native Kidneys in a Renal Transplant 
Recipient: One Swallow Does Not Make a Spring
Alexandre Persu,1,2 Jean-Philippe Lengelé,2,3 Yu Jin,4 Nada Kanaan,5 and Jan A. Staessen4,6
Publication of the Symplicity HTN-11 and HTN-22 tri-
als showed the feasibility of catheter-based renal sympa-
thetic denervation (RDN) in patients with drug-resistant 
hypertension and unleashed an unprecedented wave of 
enthusiasm. Advocates of the technique, driven by legions 
of marketers, proposed numerous potential applications of 
RDN, including atrial fibrillation, heart failure, metabolic 
syndrome and diabetes mellitus, obstructive sleep apnea, 
and even polycystic ovary syndrome. In this issue of the 
Journal, Portasiewicz and colleagues3 report the first case 
of RDN of the native kidneys in a 58-year-old kidney graft 
recipient. Before the procedure, blood pressure remained 
uncontrolled despite substitution of cyclosporine with 
tacrolimus and prescription of 5 antihypertensive drug 
classes. Renal function was altered, partly because of allo-
graft rejection, with an estimated glomerular filtration rate 
(eGFR) of 38 ml/min/1.73m2. Using the Symplicity system, 
radiofrequency energy was applied at 6 different locations 
in the right renal artery and at 5 sites in the left renal artery. 
Twenty-four-hour ambulatory blood pressure decreased by 
20/15 mm Hg at 3 months and by 16/12 mm Hg at 6 months, 
left ventricular mass declined, and antihypertensive drug 
treatment was tapered to 2 drugs, whereas eGFR remained 
unchanged (39 ml/min/1.73m2) at 6 months.
This “first-in-man” case report3 leaves several questions 
unanswered. The authors did not report on urinary sodium 
excretion and therefore did not exclude excessive salt intake, 
which is a major cause of treatment resistance, especially 
in patients with chronic kidney disease.4 Furthermore, one 
wonders why the Polish investigators did not try using angi-
otensin-converting enzyme inhibitors, an established blood 
pressure–lowering treatment in kidney transplant recipients,5 
or use thiazide instead of loop diuretics. Besides stenosis of 
the artery of the renal graft, other less frequent causes of sec-
ondary hypertension in kidney transplant recipients should 
have been excluded, in particular pheochromocytoma, 
which can cause resistant hypertension and recurrent hyper-
tensive crises.6 Finally, the authors did not assess adherence, 
for instance by measuring drug levels in urine or witnessing 
drug intake,7 nor did they use single-pill drug combinations 
that improve adherence to treatment.
Although the authors must be complimented on bringing 
their case report to publication, the clinical implications are 
minimal. The short follow-up of 6 months, the unstandard-
ized method of blood pressure measurement, the absence 
of a strategy to taper antihypertensive drug treatment after 
the procedure, and the lack of imaging of the native kidneys 
at 6 months hamper the extrapolation of the case report to 
clinical practice.
It has been suggested that the RDN might be particu-
larly efficient in patients with chronic kidney disease 
because this condition is characterized by inappropriate 
sympathetic activation and because afferent denervation 
in animal models of chronic kidney disease produced 
promising results.8 Several authors also highlighted the 
potential interest of RDN in renal transplant recipients.9 
Indeed, in this population, hypertension is frequent, often 
treatment resistant, and associated with deterioration of 
the graft function.5 Although the renal transplant itself 
is denervated, the native kidneys may still cause activa-
tion of the sympathetic nervous system through afferent 
signaling, thereby contributing to the maintenance of 
high blood pressure.5 Previous studies in kidney trans-
plant recipients10 showed a decrease in peripheral arterial 
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resistance and blood pressure after nephrectomy of the 
native kidneys, likely because of normalization of sym-
pathetic nervous activity.11 Furthermore, altered renal 
function and hypertension triggered by immunosuppres-
sive drugs, in particular cyclosporine, are at least partly 
mediated by increased sympathetic tone.5 Inhibition of 
the sympathetic nervous system may thus counteract 
several pathways contributing to post-transplant hyper-
tension. However, the enthusiasm for this potential new 
application of RDN should be viewed within the context of 
potential procedural pitfalls linked to progressive shrink-
ing of arteries of the native kidneys, low renal plasma flow, 
the difficulty to perform a complete denervation, and the 
increased risk of spasm and vascular damage.12 A  report 
by Schlaich and colleagues illustrated the soundness of 
these concerns.12 These investigators attempted to per-
form RDN in 12 patients with end-stage renal disease 
and uncontrolled blood pressure. Three patients were 
deemed ineligible because of dual renal arteries (n  =  1) 
or renal artery diameters of <4 mm at both sides (n = 2). 
Furthermore, in 2 of 9 patients who underwent RDN, the 
2-minute ablation periods were prematurely aborted on 
3 occasions because of rapidly rising temperature levels, 
most likely because of the lack of cooling by the reduced 
renal blood flow. Also, despite the theoretical interest of 
RDN in patients with chronic kidney disease,8 renal dys-
function at baseline may negatively influence the outcome. 
Indeed, in the European Network COordinating research 
on Renal Denervation (ENCOReD) registry, lower eGFR 
predicted a decreased likelihood of a favorable blood pres-
sure response to RDN.13
In conclusion, one swallow does not make a spring. A sin-
gle case of successful RDN in a kidney graft recipient is 
nothing more than a hypothesis-generating observation and 
should certainly not be considered as an incentive to per-
form RDN in transplanted patients outside the framework 
of randomized clinical trials. Several factors, including age, 
duration of hypertension, time elapsed since end-stage renal 
disease, and transplantation, may all affect the technical 
feasibility, the blood pressure response, and the renal out-
comes of RDN in this particular patient group. On 9 January 
2014, Medtronic announced that Symplicity HTN-314 failed 
to meet its primary efficacy endpoint (http://www.tctmd.
com/show.aspx?id=123265), which was defined as baseline-
adjusted between-group difference in office systolic blood 
pressure of ≥5 mm Hg. Symplicity HTN-314 is a randomized 
trial including 535 resistant hypertensive patients rand-
omized to RDN or control (sham) in a ratio of 2:1, with the 
goal to evaluate the efficacy and safety of RDN in treatment 
of resistant hypertension. The failure of Symplicity HTN-3 to 
reach its primary efficacy endpoint15 shows the gap between 
expectations raised by case reports and small uncontrolled 
observational studies and results produced by a rigorous 
study with blinded endpoint assessment. It implies that even 
in resistant hypertensive patients with fewer comorbidities 
and a less complex underlying disease process than kidney 
transplant recipients, RDN cannot be applied in routine clin-
ical practice, but only within the context of clinical research. 
Overoptimistic views have been abandoned, and the results 
of randomized controlled trials devoted to the efficacy and 
safety of RDN in renal transplants recipients (ISAR-HTN; 
NCT 01899456) are still awaited.
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